AKT1 and colorectal cancer: For instance, Yuanet al. [37] reported that elevated level of STC2 activates the PI3K/AKT pathway, leading to increased expression of the drug-resistant protein P-gp and enhanced resistance of colorectal cancer cells to oxaliplatin.